Caris Life Sciences, Inc. (CAI): who owns it and who trades it
As of Nov 16, 2026, CAI insiders reported 7 open-market sales worth $28.9M and 2 purchases worth $1.5M in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was David Baxley Spetzler (President), with $14.8M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Caris Life Sciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CAI
244 funds and institutions reported CAI shares worth $2.6B at the end of Q2 2026, about 52% of the company. The largest holder is FMR LLC (Fidelity) with 10.9%.
Funds and institutions (13F) 52%Everyone else 48%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 30.92M | 10.94% | $551M | +0% |
| J. H. Whitney Equity Partners VI, LLC | 11.26M | 3.98% | $201M | -38% |
| Coatue Management LLC | 9.82M | 3.48% | $175M | No change |
| Braidwell LP | 8.26M | 2.92% | $147M | +3% |
| PointState Capital LP | 6.83M | 2.42% | $122M | -7% |
| JPMorgan Chase & Co | 6.56M | 2.32% | $120M | – |
| BlackRock, Inc. | 5.54M | 1.96% | $98.7M | +14% |
| T. Rowe Price Investment Management, Inc. | 5.08M | 1.80% | $90.5M | -9% |
| Vanguard Portfolio Management LLC | 4.84M | 1.71% | $86.3M | +29% |
| Vanguard Capital Management LLC | 4.28M | 1.51% | $76.3M | +29% |
| Los Angeles Capital Management LLC | 3.96M | 1.40% | $70.5M | +73% |
| Neuberger Berman Group LLC | 3.59M | 1.27% | $64M | No change |
| Orbimed Advisors LLC | 2.81M | 0.99% | $50M | No change |
| BNP Paribas Financial Markets | 2.37M | 0.84% | $42.2M | +47% |
| Millennium Management LLC | 2.20M | 0.78% | $39.3M | +44% |
| Mak Capital One LLC | 1.94M | 0.69% | $34.5M | – |
| Morgan Stanley | 1.94M | 0.68% | $34.5M | +79% |
| Duquesne Family Office LLC | 1.89M | 0.67% | $33.8M | No change |
| Clearbridge Investments, LLC | 1.60M | 0.56% | $28.4M | +3% |
| FIL Ltd | 1.55M | 0.55% | $27.6M | +0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CAI insiders reported $1.5M of open-market purchases and $28.9M of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | John Russel Denton | See Remarks | Sale | 7,500 | $31.82 | $239K | Form 4 |
| Sep 17, 2026 | Brian J Brille | Director | Sale | 400,000 | $30.33 | $12.1M | Form 4 |
| Sep 4, 2026 | David Baxley Spetzler | President | Sale | 119,212 | $24.76 | $3M | Form 4 |
| Sep 3, 2026 | David Baxley Spetzler | President | Sale | 393,100 | $24.76 | $9.7M | Form 4 |
| Sep 3, 2026 | David Baxley Spetzler | President | Sale | 84,900 | $25.32 | $2.1M | Form 4 |
| May 15, 2026 | Jon Halbert | Director | Purchase | 68,000 | $14.56 | $990K | Form 4 |
| May 11, 2026 | Jeff L Vacirca | Director | Purchase | 31,050 | $16.15 | $501K | Form 4 |
| Dec 11, 2025 | Luke Thomas Power | See Remarks | Sale plan | 1,400 | $27.16 | $38K | Form 4 |
| Dec 11, 2025 | Luke Thomas Power | See Remarks | Sale plan | 60,850 | $26.56 | $1.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David Baxley Spetzler | President | – | $14.8M | Sep 4, 2026 |
| Brian J Brille | See Remarks, Director | – | $12.1M | Sep 17, 2026 |
| Luke Thomas Power | See Remarks | – | $1.7M | Dec 11, 2025 |
| Jon Halbert | Director | $990K | – | May 15, 2026 |
| Jeff L Vacirca | Director | $501K | – | May 11, 2026 |
| John Russel Denton | See Remarks | – | $239K | Sep 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CAI short interest
Low short interest. 4.1% of CAI shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.49M CAI shares were sold short, 4.1% of the shares outstanding, down 15.4% from the report before. At the average daily volume of 2.89M shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.49M | 4.07% | -15% | 2.89M | 4.0 |
| Oct 15, 2026 | 13.59M | 4.81% | -2% | 4.21M | 3.2 |
| Sep 30, 2026 | 13.89M | 4.92% | +4% | 5.59M | 2.5 |
| Sep 15, 2026 | 13.33M | 4.72% | -3% | 4.43M | 3.0 |
| Aug 31, 2026 | 13.68M | 4.84% | -8% | 5.59M | 2.5 |
| Aug 14, 2026 | 14.95M | 5.29% | +1% | 5.89M | 2.5 |
| Jul 31, 2026 | 14.76M | 5.22% | +26% | 3.51M | 4.2 |
| Jul 15, 2026 | 11.73M | 4.15% | -17% | 3.46M | 3.4 |
| Jun 30, 2026 | 14.18M | 5.02% | +22% | 3.27M | 4.3 |
| Jun 15, 2026 | 11.64M | 4.12% | +8% | 2.62M | 4.4 |
| May 29, 2026 | 10.73M | 3.80% | -9% | 2.59M | 4.2 |
| May 15, 2026 | 11.75M | 4.16% | -8% | 3.69M | 3.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Caris Life Sciences company events
Caris Life Sciences filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Sep 14, 2026AnnouncementShared information with investors. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 2, 2026AgreementCaris Life Sciences, Inc., a Texas corporation entered into a Financing Agreement, dated as of the Closing Date, by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Caris Life Sciences financials
Famous investors that hold CAI
4 of the 50 well-known investors we track reported holding CAI in their latest 13F filing. The largest position is Israel Englander's, worth $47.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.57M | $47.9M | 0.0% | -29% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 656,500 | $20.1M | 0.0% | +16% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 653,413 | $20M | 0.0% | +119% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 162,974 | $5M | 0.0% | +62% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CAI in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 13.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 13.4% |
Questions about Caris Life Sciences, Inc. (CAI) stock
Who owns the most CAI stock?
The largest reported owner of Caris Life Sciences, Inc. (CAI) is FMR LLC (Fidelity), with 10.9% of the company. In total, 244 funds and institutions reported holding CAI at the end of Q2 2026, together about 52% of the shares. See the largest owners.
Are CAI insiders buying or selling?
In the last 12 months, CAI insiders reported 2 open-market purchases worth $1.5M and 7 sales worth $28.9M. The latest trade was on Sep 22, 2026. See every trade.
What is the short interest in CAI?
As of Oct 30, 2026, 11.49M CAI shares were sold short, 4.1% of the shares outstanding, down 15.4% from the report before. At the average daily volume of 2.89M shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold CAI?
4 of the 50 well-known investors we track reported CAI in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $47.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.